NervGen Pharma(NASDAQ) NGEN

Market Cap$141.37M

Since IPO (2019)+29%

5 Year+14%

1 Year-24%

1 Month-14%

$1.71

+1.79%

+0.03Today

After hours$1.73+$0.02 (+1.17%)

NervGen Pharma last closing stock price
Metric	Price	Date
Last close	USD 1.72	2026-08-06

NervGen Pharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+7.5%	USD 1.60	2026-07-30
1 month	-14.43%	USD 2.01	2026-07-07
3 month	-54.13%	USD 3.75	2026-05-08
Year to date	-69.29%	USD 5.60	2025-12-31
1 year	-23.79%	USD 2.26	2025-08-06
3 year	+37.6%	USD 1.25	2023-08-07
5 year	+13.91%	USD 1.51	2021-08-06
Since inception	+29.16%	USD 1.30	2019-04-03

NervGen Pharma Financials at a Glance

Market Cap

$141.37M

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$46.72M

EPS (TTM)

-$0.40

P/E Ratio

-4.31

Dividend

$0.00

Beta (Volatility)

0.56 (Low)

Dividend

$0.00

Beta (Volatility)

0.56 (Low)

Price

$1.71

Volume

229

Open

$1.68

Price

$1.71

Volume

229

Open

$1.68

Previous Close

$1.72

Daily Range

$1.66 - $1.76

52-Week Range

$1.58 - $6.30

Estimated Earnings Date

Aug 21, 2026

Dividend

$0.00

Beta (Volatility)

0.56 (Low)

Price

$1.71

Volume

229

Open

$1.68

Previous Close

$1.72

Daily Range

$1.66 - $1.76

52-Week Range

$1.58 - $6.30

Estimated Earnings Date

Aug 21, 2026

NGEN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NervGen Pharma

NervGen Pharma Corp. is a biotechnology company focused on developing innovative therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. The company aims to enhance the nervous system's natural repair mechanisms through its unique approach.

Products and Services

Therapeutic solutions for nerve injuries
Innovative treatments for neurodegenerative diseases
Research and development in biotechnology

Growth Outlook

Strong pipeline of clinical development projects
Potential market expansion in neurodegenerative therapies
Increasing demand for innovative nerve repair solutions

Financial Highlights

Market capitalization of approximately $142 million
Cash and short-term investments of $16.5 million as of March 2026
Recent quarterly net income loss of CAD 1.7 million

NervGen Pharma Corp. operates in a promising sector with a focus on addressing significant medical needs. The company's innovative approach to nerve repair positions it well within the biotechnology industry. With a market capitalization of around $142 million, NervGen is actively developing its product pipeline, which could lead to substantial growth opportunities. The recent cash position of $16.5 million indicates a solid foundation for ongoing research and development efforts. However, the company has reported net income losses, reflecting the typical challenges faced by biotech firms in their early stages. Overall, NervGen Pharma Corp. presents an intriguing opportunity for investors interested in the biotechnology sector.

AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Adam Rogers, MD

Website

www.nervgen.com

Headquarters

West Vancouver, BC V6Z 2R4, CA

NGEN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-17536.81%

Return on Capital

-719.57%

Return on Assets

-190.08%

Earnings Yield

-23.20%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$141.37M

Shares Outstanding

82.19M

Volume

229

Avg. Volume

952.74K

Financials (TTM)

Gross Profit

-CA$12.21K

Operating Income

-CA$32.04M

EBITDA

-CA$8.24M

Operating Cash Flow

-CA$27.47M

Capital Expenditure

CA$4.18

Free Cash Flow

-CA$27.47M

Cash & ST Invst.

CA$16.55M

Total Debt

CA$0.00

NervGen Pharma Performance Analysis

NervGen Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	CAD 0	N/A
2023	2023-12-31	CAD 0	N/A
2024	2024-12-31	CAD 0	N/A
2025	2025-12-31	CAD 0	N/A

NervGen Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

NervGen Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	CAD -0.30	17.0%
2023	2023-12-31	CAD -0.28	-7.5%
2024	2024-12-31	CAD -0.26	-6.0%
2025	2025-12-31	CAD -0.44	66.0%

NervGen Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-134.2%
Q3	2025-09-30	56.2%
Q4	2025-12-31	-673.3%
Q1	2026-03-31	95.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$14.18K

-2.3%

Gross Margin

0.00%

N/A

Market Cap

$141.37M

N/A

Market Cap/Employee

$20.20M

N/A

Employees

N/A

Net Income

-CA$1.70M

+56.6%

EBITDA

-CA$1.69M

+56.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

CA$16.55M

+14.4%

Total Debt

CA$0.00

-100.0%

Accounts Receivable

CA$93.47K

-71.8%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$0.00

-100.0%

Return on Assets

-1.90%

N/A

Return on Invested Capital

-7.21%

N/A

Free Cash Flow

-CA$8.34M

-103.6%

Operating Cash Flow

-CA$8.34M

-103.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,715.71-0.00%

^DJIDJI

^DJIDJI$53,946.95-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,362.59-0.00%

BTCBitcoin

BTCBitcoin$64,490.00-0.00%

SPCXSPCX

SPCXSPCX$109.93+0.02%

AAPLAAPL

AAPLAAPL$311.99+0.00%

AMZNAMZN

AMZNAMZN$271.70-0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TTDThe Trade Desk

TTDThe Trade Desk$17.67-0.07%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$114.92+0.06%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$26.93-0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$72.03-0.01%

NOKNokia

NOKNokia$9.43-0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$38.70+0.01%

INTCIntel

INTCIntel$99.81-0.01%

Questions About NGEN

What is the current price of NervGen Pharma?

NervGen Pharma is trading at $1.72 per share.

What is the 52-week range for NervGen Pharma?

Over the past 52 weeks, NervGen Pharma has traded between $1.58 and $6.30.

How much debt does NervGen Pharma have?

As of the most recent reporting period, NervGen Pharma reported total debt of CA$0.00.

How much cash does NervGen Pharma have on hand?

NervGen Pharma reported CA$11.87M in cash and cash equivalents in its most recent financial results.

What is NervGen Pharma’s dividend yield?

NervGen Pharma does not currently have a dividend yield.

NervGen Pharma(NASDAQ) NGEN

NervGen Pharma Financials at a Glance

NGEN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About NervGen Pharma

NGEN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

NervGen Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NGEN

What is the current price of NervGen Pharma?

What is the 52-week range for NervGen Pharma?

How much debt does NervGen Pharma have?

How much cash does NervGen Pharma have on hand?

What is NervGen Pharma’s dividend yield?

Premium Investing Services